308430
CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clin… Read more
308430 (308430) - Net Assets
Latest net assets as of March 2025: ₩28.14 Billion KRW
Based on the latest financial reports, 308430 (308430) has net assets worth ₩28.14 Billion KRW as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩33.84 Billion) and total liabilities (₩5.69 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩28.14 Billion |
| % of Total Assets | 83.17% |
| Annual Growth Rate | 228.37% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 60.34 |
308430 - Net Assets Trend (2022–2024)
This chart illustrates how 308430's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 308430 (2022–2024)
The table below shows the annual net assets of 308430 from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩29.58 Billion | +294.47% |
| 2023-12-31 | ₩7.50 Billion | +173.79% |
| 2022-12-31 | ₩2.74 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to 308430's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1105926349000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩6.40 Billion | 21.64% |
| Other Components | ₩66.74 Billion | 225.68% |
| Total Equity | ₩29.58 Billion | 100.00% |
308430 Competitors by Market Cap
The table below lists competitors of 308430 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Tong Ren Tang Chinese Medicine Company Limited
PINK:BJTRF
|
$153.70 Million |
|
Westwing Group AG
F:WEW
|
$153.82 Million |
|
Xuchang Ketop Testing Research Ins
SHE:003008
|
$153.91 Million |
|
Designer Brands Inc
NYSE:DBI
|
$153.96 Million |
|
Guangdong Yantang Dairy Co Ltd
SHE:002732
|
$153.64 Million |
|
Newbury Street II Acquisition Corp Class A Ordinary Shares
NASDAQ:NTWO
|
$153.59 Million |
|
Washington Real Estate Investment Trust
F:WRI
|
$153.56 Million |
|
Mega-info Media Co.Ltd.
SHE:301102
|
$153.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 308430's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,497,483,910 to 29,575,125,710, a change of 22,077,641,800 (294.5%).
- Net loss of 7,266,102,150 reduced equity.
- Share repurchases of 28,120,697,510 reduced equity.
- Other factors increased equity by 57,464,441,460.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-7.27 Billion | -24.57% |
| Share Repurchases | ₩28.12 Billion | -95.08% |
| Other Changes | ₩57.46 Billion | +194.3% |
| Total Change | ₩- | 294.47% |
Book Value vs Market Value Analysis
This analysis compares 308430's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 11.95x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 128.39x to 11.95x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | ₩214.96 | ₩27600.00 | x |
| 2023-12-31 | ₩588.55 | ₩27600.00 | x |
| 2024-12-31 | ₩2310.37 | ₩27600.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 308430 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -317.32%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.16x
- Recent ROE (-24.57%) is above the historical average (-102.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -233.05% | -362.02% | 0.18x | 3.67x | ₩-6.66 Billion |
| 2023 | -48.45% | -246.92% | 0.13x | 1.51x | ₩-4.38 Billion |
| 2024 | -24.57% | -317.32% | 0.07x | 1.16x | ₩-10.22 Billion |
Industry Comparison
This section compares 308430's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 308430 (308430) | ₩28.14 Billion | -233.05% | 0.20x | $153.64 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |